STOCK TITAN
  1. Home
  2. News
  3. BTAI

BioXcel Therapeutics to Host Third Quarter 2020 Operating and Financial Results Conference Call and Webcast

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

NEW HAVEN, Conn., Nov. 05, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced it will host a conference call and webcast on Thursday, November 12, 2020 at 8:30 AM Eastern Time to discuss its third quarter 2020 operating and financial results.

Conference Call & Webcast Details
Date/Time: Thursday, November 12, 2020, 8:30 AM Eastern Time
Domestic: 877-407-2985
International: 201-378-4915
The webcast will be accessible* under "Events" on the News & Media page of the Company's website at www.bioxceltherapeutics.com.

Replay
Domestic: 877-660-6853
International: 201-612-7415
Conference ID: 13712147
*Replay available through at least November 26, 2020

BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. BTI's drug re-innovation approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI's two most advanced clinical development programs are BXCL501, an investigational sublingual thin film formulation in development for acute treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an investigational orally administered systemic innate immunity activator in development for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer in combination with other immuno-oncology agents. For more information, please visit www.bioxceltherapeutics.com.

Contact Information:

BioXcel Therapeutics, Inc.
www.bioxceltherapeutics.com

Investor Relations:
John Graziano
jgraziano@troutgroup.com
1.646.378.2942

Media:
Julia Deutsch
jdeutsch@troutgroup.com
1.646.378.2967

Stock BTAI logo
BioXcel Therapeutics, Inc.

NASDAQ:BTAI

BTAI Rankings

#4470 Ranked by Market Cap
#5252 Ranked by Stock Gains
N/A Ranked by Dividends

BTAI Latest News

May 9, 2024
BioXcel Therapeutics Reports First Quarter 2024 Financial Results
Apr 25, 2024
BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024
Apr 24, 2024
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting
Apr 22, 2024
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential
Mar 25, 2024
BioXcel Therapeutics Announces $25 Million Registered Direct Offering

BTAI Stock Data

79.94M
21.69M
27.01%
28.51%
8.15%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
NEW HAVEN

About BTAI

bioxcel therapeutics, inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. the company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. the company's two most advanced clinical development programs are bxcl501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and bxcl701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.